ICAP
CLDX icon

Independence Capital Asset Partners’s Celldex Therapeutics CLDX Stock Holding History

Independence Capital Asset Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-15,045
Closed -$6.29M – 42
2015
Q1 		$6.29M Buy
+15,045
New +$5.38M 0.98% 39

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Independence Capital Asset Partners's CLDX Position: Q2 2015 in Review

Independence Capital Asset Partners sold out of Celldex Therapeutics (CLDX) in Q2 2015, closing a stake of 15,045 shares — an estimated $6.29M sold.

Independence Capital Asset Partners first reported a position in CLDX in Q1 2015 and held it in 1 quarter. The position peaked at $6.29M in Q1 2015. 186 funds tracked by Wall St. Rank hold CLDX as of Q2 2015.

  • Independence Capital Asset Partners reported no remaining Celldex Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Independence Capital Asset Partners sold 15,045 Celldex Therapeutics shares in Q2 2015, an estimated $6.29M.
  • Independence Capital Asset Partners first reported a position in Celldex Therapeutics in Q1 2015 and held it in 1 quarter.
  • Independence Capital Asset Partners's Celldex Therapeutics position peaked at $6.29M in Q1 2015.
  • 186 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2015.

Based on Independence Capital Asset Partners's 13F filing for Q2 2015, filed 13 Aug 2015.